Why Veru Stock Surged Today

1 min read

Shares of Veru (NASDAQ: VERU) jumped 38.4% on Tuesday following positive analyst commentary. 

H.C. Wainwright analyst Yi Chen says investors should buy Veru’s shares following the biotech company’s promising phase 2 clinical trial results for VERU-111, its investigational oral drug for COVID-19 patients at high risk for acute respiratory distress syndrome.

Chen boosted his price forecast for Veru’s stock from $12 to $17 after hospitalized COVID-19 patients treated with VERU-111 saw an 81% reduction in death or respiratory failure compared to those who received a placebo. 

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

nVent Electric plc (NVT) Q4 2020 Earnings Call Transcript

Next Story

Why Shopify Stock Rose to a New All-Time High Today

Latest from Blog